Current Issue - November 2020, Volume 14, Issue No. 3

1. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am. 1987; 69(1): 106-14.
2. Turcotte RE. Giant cell tumour of bone. Orthop Clin North Am. 2006; 37: 35-51. doi: 10.1016/j.ocl.2005.08.005
3. Saiz P, Virkus W, Piasecki P, Templeton A, Shott A, Gitelis S. Results of Giant cell tumours treated with intralesional excision. Clin Orthop Relat Res. 2004; (424): 221-6. doi: 10.1097/01.blo.0000128280.59965.e3
4. Capanna R, Sudanese A, Baldini N, Campanacci M. Phenol as an adjuvant in the control of local recurrence of benign neoplasm of bone treated by curettage. Ital J Orthop Traumatol. 1985; 11(3): 381-8.
5. Gouin F, Dumaine V, French Sarcoma Group. Local recurrence after curettage treatment of giant cell tumors in peripheral bones: retrospective study by the GSF-GETO (French Sarcoma and Bone Tumor Study Group). Orthop Traumatol Surg Res. 2013; 99(6 Suppl): S313-318. doi: 10.1016/j.otsr.2013.07.006
6. Gao ZH, Yin JQ, Xie XB, Zou CY, Huang G, Wang J, et al. Local control of giant cell tumors of the long bone after aggressive curettage with and without bone cement. BMC Musculoskeletal Disord. 2014; 15: 330. doi: 10.1186/1471-2474-15-330
7. Steyern FV, Bauer HC, Trovik C, Kivioja A, Bergh P, Jorgensen PH. Treatment of local recurrences of GCT in long bones after curettage and cementing. A scandinavian sarcoma group study. J Bone Joint Surg Br. 2006; 88: 1656-8. doi: 10.1302/0301-620X.88B4.17407
8. Deheshi BM, Jaffer SN, Griffin AM, Ferguson PC, Bell RS, Wunder JS. Joint salvage for pathologic fracture of giant cell tumor of the lower extremity. Clin Orthop Relat Res. 2007; 459: 96-104. doi: 10.1097/BLO.0b013e31805d85e4
9. Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM. Bisphosphonates induce apoptosis of stromal tumour cells in giant cell tumour of Bone. Calcif Tissue Int. 2004; 75: 71-7. doi: 10.1007/s00223-004-0120-2
10. Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone. 2007; 42: 68-73. doi: 10.1016/j.bone.2007.08.038
11. Gouin F, Rochwerger AR, Di Marco A, Rosset P, Bonnevialle P, Fiorenza F, et al. Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone. Eur J Cancer. 2014; 50: 2425-31. doi: 10.1016/j.ejca.2014.06.003
12. Yu X, Xu M, Xu S, Su Q. Clinical outcomes of giant cell tumor of bone treated with bone cement filling and internal fixation, and oral bisphosphonates. Oncol Lett. 2013; 5: 447-51. doi: 10.3892/ol.2012.1036
13. Kundu ZS, Sen R, Dhiman A, Sharma P, Siwach R, Rana P. Effect of intravenous Zoledronic acid on histopathology and recurrence after extended curettage in giant cell tumors of bone: A comparative prospective study. Indian J Orthop. 2018; 52(1): 45-50. doi: 10.4103/ortho.IJOrtho_216_17
14. Nishisho T, Hanaoka N, Miyagi R, Sakai T, Toki S, Takahashi M, et al. Local administration of zoledronic acid for giant cell tumor of bone. Orthopedics. 2015; 38(1): e25-30. doi: 10.3928/01477447-20150105-56
15. Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, et al. Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clin Sarcoma Res. 2016; 6(1): 15. doi: 10.1186/s13569-016-0056-0
16. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of Denosumab for adults and skeletally mature adolescents with giant cell tumor of bone: interim analysis of open-label parallel-group, phase 2 study. Lancet Oncol. 2013; 14(9): 901-8. doi: 10.1016/S1470-2045(13)70277-8
17. Prosser GH, Baloch KG, Tillman RM, Carter SR, Grimer RJ. Does curettage without adjuvant therapy provide low recurrence rates in giant cell tumors of bone? Clin Ortho Relat Res. 2005; 435: 211-8. doi: 10.1097/01.blo.0000160024.06739.ff
18. Bini SA, Gill K, Johnston JO. Giant cell tumor of bone. Curettage and cement Reconstruction. Clin Orthop Relat Res. 1995; (321): 245-50.
19. Radev BR, Kase JA, Askew MJ, Weiner SD. Potential for thermal damage to articular cartilage by PMMA reconstruction of a bone cavity following tumor excision: A finite element study. J Biomech. 2009; 42: 1120-6. doi: 10.1016/j.jbiomech.2009.02.005
20. Krieg AH, Hefti F. Reconstruction with non-vascularised fibular grafts after resection of bone tumours. J Bone Joint Surg Br. 2007; 89(2): 215-21. doi: 10.1302/0301-620X.89B2.17686
21. Verma AK, Kushwaha NS, Saini A, Waliullah S, Navadaya MK, Kumar D. Retrospective analysis of donor site morbidity following partial fibular resection. Int J Contemp Med Res. 2016; 3: 1571-4.
22. Shingade VU, Jagtap SM, Ranade AB. Weakness of extensor hallucis longus after removal of non-vascularised fibula as an autograft. J Bone Joint Surg Br. 2004; 86(3): 384-7. doi: 10.1302/0301-620x.86b3.14748
23. Saibaba B, Chouhan DK, Kumar V, Dhillon MS, Rajoli SR. Curettage and reconstruction by the sandwich technique for giant cell tumours around the knee. J Orthop Surg. 2014; 22: 351-5. doi: 10.1177/230949901402200317

Abstract   |   Reference